Literature DB >> 12906930

Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study.

Chikai Sakurada1, Shinobu Sakurada, Takafumi Hayashi, Sou Katsuyama, Koichi Tan-No, Tsukasa Sakurada.   

Abstract

Endomorphin-2 (Tyr-Pro-Phe-PheNH(2)) was discovered as an endogenous ligand for the mu-opioid receptor. The physiological function of endomorphin-2 as a neurotransmitter or neuromodulator may cease through the rapid enzymatic process in the synapse of brain, as for other neuropeptides. The present study was conducted to examine the metabolism of endomorphin-2 by synaptic membranes prepared from mouse brain. Major metabolites were free tyrosine, free phenylalanine, Tyr-Pro and PheNH(2). Both the degradation of endomorphin-2 and the accumulation of major metabolites were inhibited by specific inhibitors of dipeptidyl peptidase IV, such as diprotin A and B. On the other hand, the accumulation of Phe-PheNH(2) and Pro-Phe-PheNH(2) was increased in the presence of bestatin, an aminopeptidase inhibitor, whereas that of free phenylalanine and PheNH(2) was decreased. Furthermore, purified dipeptidyl peptidase IV hydrolyzed endomorphin-2 at the cleavage site, Pro(2)-Phe(3) bond. Thus, degradation of endomorphin-2 by brain synaptic membranes seems to take place mainly through the cleavage of Pro(2)-Phe(3) bond by dipeptidyl peptidase IV, followed by release of free phenylalanine and PheNH(2) from the liberated fragment, Phe-PheNH(2) by aminopeptidase. We have also examined that the effect of diprotin A on the antinociception induced by intracerebroventricularly administered endomorphin-2 in the mouse paw withdrawal test. Diprotin A simultaneously injected with endomorphin-2 enhanced endomorphin-2-induced antinociception. These results indicate that dipeptidyl peptidase IV may be an important peptidase responsible for terminating endomorphin-2-induced antinociception at the supraspinal level in mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906930     DOI: 10.1016/s0006-2952(03)00391-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Kinetic studies of novel inhibitors of endomorphin degrading enzymes.

Authors:  Renata Perlikowska; Jakub Fichna; Jean Claude do-Rego; Katarzyna Gach; Anna Janecka
Journal:  Med Chem Res       Date:  2011-05-20       Impact factor: 1.965

Review 2.  Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.

Authors:  Ashwani Sharma; Tarun Virmani; Anjali Sharma; Vaishnavi Chhabra; Girish Kumar; Kamla Pathak; Abdulsalam Alhalmi
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-16       Impact factor: 3.249

Review 3.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

4.  The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.

Authors:  Hong Xie; James H Woods; John R Traynor; Mei-Chuan Ko
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

5.  The effects of endomorphins on striatal [3H]GABA release induced by electrical stimulation: an in vitro superfusion study in rats.

Authors:  Zsolt Bagosi; Miklós Jászberényi; Gyula Telegdy
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

6.  The Analgesic Activity of Bestatin as a Potent APN Inhibitor.

Authors:  Mei-Rong Jia; Tao Wei; Wen-Fang Xu
Journal:  Front Neurosci       Date:  2010-06-28       Impact factor: 4.677

7.  Biotransformation of beta-endorphin and possible therapeutic implications.

Authors:  Naghmeh H Asvadi; Michael Morgan; Amitha K Hewavitharana; P Nicholas Shaw; Peter J Cabot
Journal:  Front Pharmacol       Date:  2014-02-19       Impact factor: 5.810

8.  Beta-endorphin 1-31 biotransformation and cAMP modulation in inflammation.

Authors:  Naghmeh Hajarol Asvadi; Michael Morgan; Herath M Herath; Amitha K Hewavitharana; P Nicholas Shaw; Peter J Cabot
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 9.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Authors:  Martín Candia; Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-09-20       Impact factor: 2.749

Review 10.  Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain.

Authors:  Pegah Varamini; Istvan Toth
Journal:  Front Pharmacol       Date:  2013-12-13       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.